Regulation & Compliance

Early trial data for a novel antibody-drug conjugate shows a 32% response rate in a hard-to-treat patient group, signaling a potential new front in precision oncology.

Zurich's Linvo AG is betting its future on AI, creating 'AI Advisor' roles to redefine wealth management. Is this the dawn of a new era for Swiss finance?

Bell's latest layoffs spark union outrage, but they are just one piece of a high-stakes strategy involving AI, US investments, and a $1.5B cost-cutting plan.

A legal battle over click-and-collect rent could be the final straw for thousands of UK retailers. A deep dive into a case pitting digital reality against analog contracts.

Singaporean fintech giant UQPAY has secured regulatory approval in Australia. What does its arrival signal for local businesses and the future of global commerce?

After three decades, a new class of therapy for a rare liver disease lands in Singapore, rewriting the rules of care by targeting patient suffering, not just lab results.

Airwheel's new rideable AI Suitcase promises a revolution in airport mobility, but its advanced tech faces a harsh reality of strict airline rules and bans.

Amid trade war fallout, Canada's largest private-sector union pushes for protectionist policies. Will leveraging public contracts save jobs or spark new conflicts?

With a $150M war chest, E. Scott Crist's latest SPAC hunts for an industrial tech gem. But can a team with a mixed track record deliver in this new era?

Delisted and facing market headwinds, Allurion is executing a reverse stock split. Can this financial maneuver revive its stock and fund its U.S. expansion?

Digital Wallet Group's award-winning Smiles app is here. Can its AI tech and focus on migrant communities disrupt US giants like Western Union and Remitly?

A new report reveals a huge 'say-do gap' in AI adoption for compensation. Most firms are stalled, but not by tech or budget. The real culprit is data chaos.

A landmark settlement in Texas is part of a growing trend where massive legal awards, not just regulations, are becoming a powerful driver for corporate accountability.

Model N's acquisition of Kalderos targets the chaotic 340B drug discount program, a system where 99% of pharma leaders lack real-time data visibility.

A new partnership brings clinical AI to thousands of independent practices, promising to slash administrative costs and give doctors back their most valuable asset: time.

A new platform from Nylas gives AI agents their own email and calendar, solving a key bottleneck and unlocking compliant automation for business workflows.

With backing from tech titans, the new Appia Foundation aims to translate abstract AI principles into a verifiable, open-source accountability framework.

The traditional BPO model faces an existential crisis. As AI empowers enterprises, the demand has shifted from cheap labor to intelligent, measurable outcomes.

A new platform promises to shift influencer marketing from gut feel to data science, offering predictive ROI scores for creators with just a username.

Clear Health's Isoclear offers the power of isotretinoin without oral Accutane's strict rules, but its non-FDA-approved status raises critical questions.